| 1. | Sinha P, Kerchberger VE, Willmore A, Chambers J, Zhuo H, Abbott J, et al. Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials. Lancet Respir Med 2023;11:965–974. |
| 2. | van Amstel RBE, Kennedy JN, Scicluna BP, Bos LDJ, Peters-Sengers H, Butler JM, et al.; MARS Consortium. Uncovering heterogeneity in sepsis: a comparative analysis of subphenotypes. Intensive Care Med 2023;49:1360–1369. |
| 3. | Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011;306:2594–2605. |
| 4. | Seymour CW, Kennedy JN, Wang S, Chang CH, Elliott CF, Xu Z, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA 2019;321:2003–2017. |
| 5. | Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991;88:1747–1754. |
| 6. | Delano MJ, Ward PA. Sepsis-induced immune dysfunction: can immune therapies reduce mortality? J Clin Invest 2016;126:23–31. |
| 7. | Lira Chavez FM, Gartzke LP, van Beuningen FE, Wink SE, Henning RH, Krenning G, et al. Restoring the infected powerhouse: mitochondrial quality control in sepsis. Redox Biol 2023;68:102968. |
| 8. | Yu X, Hu X, Wang D, Cui P, Zeng M, Li M, et al. Macrophage S1PR2 drives sepsis-induced immunosuppression by exacerbating mitochondrial fragmentation. Am J Respir Cell Mol Biol 2025;72:615–626. |
| 9. | Guilliams M, Mildner A, Yona S. Developmental and functional heterogeneity of monocytes. Immunity 2018;49:595–613. |
| 10. | Villani AC, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science 2017;356:eaah4573. |
| 11. | Schmiedel BJ, Singh D, Madrigal A, Valdovino-Gonzalez AG, White BM, Zapardiel-Gonzalo J, et al. Impact of genetic polymorphisms on human immune cell gene expression. Cell 2018;175:1701–1715.e16. |
| 12. | Zhang G, Yang L, Kim GS, Ryan K, Lu S, O’Donnell RK, et al. Critical role of sphingosine-1-phosphate receptor 2 (S1PR2) in acute vascular inflammation. Blood 2013;122:443–455. |
| 13. | Skoura A, Michaud J, Im DS, Thangada S, Xiong Y, Smith JD, et al. Sphingosine-1-phosphate receptor-2 function in myeloid cells regulates vascular inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol 2011;31:81–85. |
| 14. | McGinley MP, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions. Lancet 2021;398:1184–1194. |
| 15. | Larson-Casey JL, He C, Carter AB. Mitochondrial quality control in pulmonary fibrosis. Redox Biol 2020;33:101426. |
| 16. | He C, Larson-Casey JL, Davis D, Hanumanthu VS, Longhini ALF, Thannickal VJ, et al. NOX4 modulates macrophage phenotype and mitochondrial biogenesis in asbestosis. JCI Insight 2019;4:e126551. |
| 17. | Larson-Casey JL, Gu L, Davis D, Cai GQ, Ding Q, He C, et al. Post-translational regulation of PGC-1alpha modulates fibrotic repair. FASEB J 2021;35:e21675. |
Comments
